SUSTAINED RELEASE ACEMETACIN COMPOSITIONS

The invention relates to the sustained release pharmaceutical composition comprising acemetacin or a pharmaceutically acceptable salt thereof, wherein the composition is composed of Eudragit® L100-55 (Poly(methacylic acid-co-ethyl acrylate) and Eudragit® L100 (Poly(methacylic acid-co-methyl acrylate...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	AKTAS, Tansel, KANIK, Bayram, ZOR, Ali, YILDIRIM, Ersin, ÖZTÜRK, Fatma
Format:	Patent
Sprache:	eng ; fre ; ger
Schlagworte:	HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	The invention relates to the sustained release pharmaceutical composition comprising acemetacin or a pharmaceutically acceptable salt thereof, wherein the composition is composed of Eudragit® L100-55 (Poly(methacylic acid-co-ethyl acrylate) and Eudragit® L100 (Poly(methacylic acid-co-methyl acrylate) as release modifying agents in ratio of 40:60 to 60:40 by weight. The amount of release modifying agents is between 7% - 15% w/w in the composition and the particle size of acemetacin is in the range of 100 - 200 micrometers.